Skip to main content
Quest Diagnostics

Tick-Borne Disease Molecular Testing Positivity and Coinfection Incidence in the Northeastern United States: 2021-2023

AACC/ADLM 2024

The Association for Diagnostics & Laboratory Medicine (formerly ACC)

Chicago, IL, July 28-Aug 1, 2024

Poster presentation: Tick-Borne Disease Molecular Testing Positivity and Coinfection Incidence in the Northeastern United States: 2021-2023

Authors: Pratt G, Matsushita F, Bi C, Rao LV

Specialty: Infectious disease

Related content

Publication
A Comparison of Lyme Serological Testing Platforms with a Panel of Clinically Characterized Samples from Various Stages of Lyme Disease
On-Demand Webinar
Tick-borne Illness A Panel Discussion About Emerging Diagnostics Insights
Test FAQ
Lyme Disease Testing
Publication
Utility of Whole Blood Real-Time PCR Testing for the Diagnosis of Early Lyme Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.